Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Delbaldo

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancerSandrine Faivre, Catherine Delbaldo, Karina Vera, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2010
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignanciesChristophe Le Tourneau, Sandrine Faivre, Valérie Laurence, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2005
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignanciesSandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapyJohan Vansteenkiste, Primo N Lara, Thierry Le Chevalier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma GroupJean-Yves Blay, Axel Le Cesne, Isabelle Ray-Coquard, et al.
Gynecologic Oncology|November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trialClémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Frontiers in Pharmacology|October 7, 2021
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French PatientsDominique Berton, Anne Floquet, Willy Lescaut, et al.
The New England Journal of Medicine|May 13, 2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancerThierry Conroy, Françoise Desseigne, Marc Ychou, et al.
Journal of Geriatric Oncology|April 27, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLDThomas Aparicio, Ariane Darut-Jouve, Faiza Khemissa Akouz, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancerSandrine Faivre, Catherine Delbaldo, Karina Vera, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2010
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignanciesChristophe Le Tourneau, Sandrine Faivre, Valérie Laurence, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2005
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignanciesSandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapyJohan Vansteenkiste, Primo N Lara, Thierry Le Chevalier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma GroupJean-Yves Blay, Axel Le Cesne, Isabelle Ray-Coquard, et al.
Gynecologic Oncology|November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trialClémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Frontiers in Pharmacology|October 7, 2021
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French PatientsDominique Berton, Anne Floquet, Willy Lescaut, et al.
The New England Journal of Medicine|May 13, 2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancerThierry Conroy, Françoise Desseigne, Marc Ychou, et al.
Journal of Geriatric Oncology|April 27, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLDThomas Aparicio, Ariane Darut-Jouve, Faiza Khemissa Akouz, et al.
Pageof 3